You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameVecuronium
Accession NumberDB01339
TypeSmall Molecule
GroupsApproved
DescriptionMonoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents. [PubChem]
Structure
Thumb
Synonyms
Vecuronium
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Norcuron Inj 10mg/vialpowder for solution10 mgintravenousOrganon Canada Ltd Ltee1986-12-312009-08-04Canada
Vecuronium Bromide for Injectionpowder for solution10.00 mgintravenousHospira Healthcare Corporation2000-06-01Not applicableCanada
Vecuronium Bromide for Injectionpowder for solution20.00 mgintravenousHospira Healthcare Corporation2000-01-28Not applicableCanada
Vecuronium Bromide for Injectionpowder for solution10 mgintravenousPharmaceutical Partners Of Canada Inc2000-06-132008-02-15Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Vecuroniuminjection, powder, lyophilized, for solution10 mg/10mLintravenousSagent Pharmaceuticals2011-08-01Not applicableUs
Vecuroniuminjection, powder, lyophilized, for solution20 mg/20mLintravenousSagent Pharmaceuticals2011-08-01Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution1 mg/mLintravenousCardinal Health2009-07-21Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution1 mg/mLintravenousPfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution1 mg/mLintravenousSun Pharma Global FZE2014-12-15Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution1 mg/mLintravenousMylan Institutional LLC2011-05-11Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution10 mg/10mLintravenousTeva Parenteral Medicines, Inc.2002-11-14Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution1 mg/mLintravenousREMEDYREPACK INC.2015-06-23Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution1 mg/mLintravenousPfizer Laboratories Div Pfizer Inc2011-05-11Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution1 mg/mLintravenousSun Pharma Global FZE2014-12-15Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution20 mg/20mLintravenousTeva Parenteral Medicines, Inc.2002-11-14Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution1 mg/mLintravenousMylan Institutional LLC2011-05-11Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution1 mg/mLintravenousMylan Institutional LLC2011-05-11Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution1 mg/mLintravenousHospira, Inc.1999-10-21Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution1 mg/mLintravenousCardinal Health2000-08-01Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution1 mg/mLintravenousAkorn Strides Llc2010-09-15Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution1 mg/mLintravenousMylan Institutional LLC2011-05-11Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution1 mg/mLintravenousHospira, Inc.1999-10-21Not applicableUs
Vecuronium Bromideinjection, powder, lyophilized, for solution10 mg/10mLintravenousCardinal Health1999-08-25Not applicableUs
Vecuronium Bromide for Injectioninjection, powder, lyophilized, for solution1 mg/mLintravenousSun Pharma Global Inc.2009-07-21Not applicableUs
Vecuronium Bromide for Injectioninjection, powder, lyophilized, for solution1 mg/mLintravenousSun Pharma Global Inc.2009-07-21Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Vecuronium bromide
50700-72-6
Thumb
  • InChI Key: VEPSYABRBFXYIB-PWXDFCLTSA-M
  • Monoisotopic Mass: 636.350171
  • Average Mass: 637.744
DBSALT001200
Categories
UNII5438723848
CAS number86029-43-8
WeightAverage: 557.8274
Monoisotopic: 557.431833322
Chemical FormulaC34H57N2O4
InChI KeyInChIKey=BGSZAXLLHYERSY-XQIGCQGXSA-N
InChI
InChI=1S/C34H57N2O4/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36/h25-32H,6-22H2,1-5H3/q+1/t25-,26+,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
IUPAC Name
1-[(1S,2S,4S,5S,7S,10R,11S,13S,14R,15S)-5,14-bis(acetyloxy)-2,15-dimethyl-4-(piperidin-1-yl)tetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-13-yl]-1-methylpiperidin-1-ium
SMILES
[H][C@@]12C[C@@H]([[email protected]](OC(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[[email protected]](OC(C)=O)[[email protected]](C[C@]12C)N1CCCCC1)[N+]1(C)CCCCC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as steroid esters. These are compounds containing a steroid moiety which bears a carboxylic acid ester group.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSteroid esters
Direct ParentSteroid esters
Alternative Parents
Substituents
  • Steroid ester
  • Androstane-skeleton
  • Cyclohexylamine
  • Piperidine
  • Acetate salt
  • Quaternary ammonium salt
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Organic cation
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationVecuronium is a muscle relaxing agent and is used as an ajunct in general anesthesia.
PharmacodynamicsVecuronium operates by competing for the cholinoceptors at the motor end plate thereby exerting its muscle-relaxing properties which are used adjunctively to general anesthesia.
Mechanism of actionVecuronium is a bisquaternary nitrogen compound that acts by competitively binding to nicotinic cholinergic receptors. The binding of vecuronium decreases the opportunity for acetylcholine to bind to the nicotinic receptor at the postjunctional membrane of the myoneural junction. As a result, depolarization is prevented, calcium ions are not released and muscle contraction does not occur.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

100%

Route of eliminationFecal (40-75%) and renal (30% as unchanged drug and metabolites)
Half life51–80 minutes
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8913
Blood Brain Barrier+0.878
Caco-2 permeable+0.5457
P-glycoprotein substrateSubstrate0.77
P-glycoprotein inhibitor IInhibitor0.6962
P-glycoprotein inhibitor IIInhibitor0.6508
Renal organic cation transporterNon-inhibitor0.6862
CYP450 2C9 substrateNon-substrate0.8382
CYP450 2D6 substrateNon-substrate0.7638
CYP450 3A4 substrateSubstrate0.742
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9229
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9368
Ames testNon AMES toxic0.7499
CarcinogenicityNon-carcinogens0.9265
BiodegradationNot ready biodegradable0.8557
Rat acute toxicity2.6653 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9021
hERG inhibition (predictor II)Non-inhibitor0.7784
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionintravenous1 mg/mL
Injection, powder, lyophilized, for solutionintravenous10 mg/10mL
Injection, powder, lyophilized, for solutionintravenous20 mg/20mL
Powder for solutionintravenous10 mg
Powder for solutionintravenous10.00 mg
Powder for solutionintravenous20.00 mg
Prices
Unit descriptionCostUnit
Vecuronium 20 mg vial5.05USD vial
Vecuronium 10 mg vial3.64USD vial
Vecuronium 10 mg/10 ml syringe2.36USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point228 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility1.86e-05 mg/mLALOGPS
logP2.07ALOGPS
logP0.89ChemAxon
logS-7.5ALOGPS
pKa (Strongest Basic)9.65ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area55.84 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity169.31 m3·mol-1ChemAxon
Polarizability66.85 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Frans Herwig Jan Jansen, “Process to prepare pharmaceutical compositions containing vecuronium bromide and compositions produced thereby.” U.S. Patent US5681573, issued January, 1969.

US5681573
General ReferencesNot Available
External Links
ATC CodesM03AC03
AHFS Codes
  • 12:20.00
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with 1,10-Phenanthroline.
AcetaminophenThe serum concentration of Vecuronium can be increased when it is combined with Acetaminophen.
AclidiniumAclidinium may increase the anticholinergic activities of Vecuronium.
AclidiniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Aclidinium.
AfatinibThe serum concentration of Vecuronium can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Vecuronium can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Vecuronium can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Vecuronium can be increased when it is combined with Alectinib.
AlfentanilThe risk or severity of adverse effects can be increased when Vecuronium is combined with Alfentanil.
AlfentanilThe serum concentration of Vecuronium can be increased when it is combined with Alfentanil.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Alphacetylmethadol.
AmantadineThe serum concentration of Vecuronium can be increased when it is combined with Amantadine.
AmbenoniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Ambenonium.
Aminohippuric acidThe serum concentration of Vecuronium can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Vecuronium can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Vecuronium can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Vecuronium can be increased when it is combined with Amlodipine.
AmprenavirThe serum concentration of Vecuronium can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Vecuronium can be increased when it is combined with Amsacrine.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Vecuronium.
AstemizoleThe serum concentration of Vecuronium can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Vecuronium can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Vecuronium can be increased when it is combined with Atenolol.
AtorvastatinThe serum concentration of Vecuronium can be increased when it is combined with Atorvastatin.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Vecuronium.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Vecuronium.
AzelastineThe serum concentration of Vecuronium can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Vecuronium can be increased when it is combined with Azithromycin.
BenactyzineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Benactyzine.
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Vecuronium.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Vecuronium.
BenzocaineThe serum concentration of Vecuronium can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Vecuronium can be increased when it is combined with Bepridil.
BezitramideThe risk or severity of adverse effects can be increased when Vecuronium is combined with Bezitramide.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Vecuronium.
BosutinibThe serum concentration of Vecuronium can be increased when it is combined with Bosutinib.
Botulinum Toxin Type AVecuronium may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BVecuronium may increase the anticholinergic activities of Botulinum Toxin Type B.
BromocriptineThe serum concentration of Vecuronium can be increased when it is combined with Bromocriptine.
BuprenorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Buprenorphine.
BuprenorphineThe serum concentration of Vecuronium can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Vecuronium can be increased when it is combined with Buspirone.
ButorphanolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Butorphanol.
CabazitaxelThe serum concentration of Vecuronium can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Vecuronium can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Vecuronium can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Vecuronium can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Vecuronium can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Vecuronium can be decreased when it is combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Vecuronium is combined with Carfentanil.
CarvedilolThe serum concentration of Vecuronium can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Vecuronium can be increased when it is combined with Caspofungin.
ChloroquineThe serum concentration of Vecuronium can be increased when it is combined with Chloroquine.
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Vecuronium.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Chlorphenoxamine.
ChlorpromazineThe serum concentration of Vecuronium can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Vecuronium can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Vecuronium can be increased when it is combined with Chlorprothixene.
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Vecuronium.
CholesterolThe serum concentration of Vecuronium can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Vecuronium can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Vecuronium can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Vecuronium can be decreased when it is combined with Cimetidine.
CimetropiumVecuronium may increase the anticholinergic activities of Cimetropium.
CiprofloxacinThe serum concentration of Vecuronium can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Vecuronium can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Vecuronium can be increased when it is combined with Clarithromycin.
ClofazimineThe serum concentration of Vecuronium can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Vecuronium can be increased when it is combined with Clomipramine.
ClotrimazoleThe serum concentration of Vecuronium can be decreased when it is combined with Clotrimazole.
CobicistatThe serum concentration of Vecuronium can be increased when it is combined with Cobicistat.
CodeineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Codeine.
ColchicineThe serum concentration of Vecuronium can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Vecuronium can be increased when it is combined with Colforsin.
CoumaphosThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Coumaphos.
CrizotinibThe serum concentration of Vecuronium can be increased when it is combined with Crizotinib.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Vecuronium.
CyclophosphamideThe serum concentration of Vecuronium can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Vecuronium can be decreased when it is combined with Cyclosporine.
DaclatasvirThe serum concentration of Vecuronium can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Vecuronium can be increased when it is combined with Dactinomycin.
DantroleneDantrolene may increase the neuromuscular blocking activities of Vecuronium.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Vecuronium.
DasatinibThe serum concentration of Vecuronium can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Vecuronium can be decreased when it is combined with Daunorubicin.
DecamethoniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Decamethonium.
DemecariumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Demecarium.
DesipramineThe serum concentration of Vecuronium can be increased when it is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Vecuronium.
DexamethasoneThe serum concentration of Vecuronium can be decreased when it is combined with Dexamethasone.
DexetimideThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dexetimide.
DextromethorphanThe serum concentration of Vecuronium can be increased when it is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dezocine.
DichlorvosThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Dichlorvos.
DiclofenacThe serum concentration of Vecuronium can be increased when it is combined with Diclofenac.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Vecuronium.
DigoxinThe serum concentration of Vecuronium can be decreased when it is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydrocodeine.
DihydroergotamineThe serum concentration of Vecuronium can be increased when it is combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Dihydromorphine.
DiltiazemThe serum concentration of Vecuronium can be increased when it is combined with Diltiazem.
DiphenoxylateThe risk or severity of adverse effects can be increased when Vecuronium is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Vecuronium can be increased when it is combined with Dipyridamole.
DonepezilThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Donepezil.
DoxazosinThe serum concentration of Vecuronium can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Vecuronium can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Vecuronium can be decreased when it is combined with Doxorubicin.
DPDPEThe risk or severity of adverse effects can be increased when Vecuronium is combined with DPDPE.
DronabinolVecuronium may increase the tachycardic activities of Dronabinol.
DronabinolThe serum concentration of Vecuronium can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Vecuronium can be increased when it is combined with Dronedarone.
EchothiophateThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Echothiophate.
EdrophoniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Edrophonium.
ElbasvirThe serum concentration of Vecuronium can be increased when it is combined with Elbasvir.
EluxadolineVecuronium may increase the constipating activities of Eluxadoline.
EnalaprilThe serum concentration of Vecuronium can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Vecuronium can be increased when it is combined with Enzalutamide.
ErgonovineThe serum concentration of Vecuronium can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Vecuronium can be increased when it is combined with Ergotamine.
ErythromycinThe serum concentration of Vecuronium can be decreased when it is combined with Erythromycin.
EstramustineThe serum concentration of Vecuronium can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Vecuronium can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Vecuronium can be decreased when it is combined with Estrone.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Vecuronium.
EthylmorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Ethylmorphine.
EtoposideThe serum concentration of Vecuronium can be increased when it is combined with Etoposide.
EtorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Etorphine.
EtravirineThe serum concentration of Vecuronium can be increased when it is combined with Etravirine.
FelodipineThe serum concentration of Vecuronium can be increased when it is combined with Felodipine.
FentanylThe risk or severity of adverse effects can be increased when Vecuronium is combined with Fentanyl.
FentanylThe serum concentration of Vecuronium can be increased when it is combined with Fentanyl.
FenthionThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Fenthion.
FesoterodineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Fesoterodine.
FexofenadineThe serum concentration of Vecuronium can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Vecuronium can be increased when it is combined with Fidaxomicin.
FluconazoleThe serum concentration of Vecuronium can be increased when it is combined with Fluconazole.
FluoxetineThe serum concentration of Vecuronium can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Vecuronium can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Vecuronium can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Vecuronium can be increased when it is combined with Flurazepam.
FluvoxamineThe serum concentration of Vecuronium can be increased when it is combined with Fluvoxamine.
GalantamineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Vecuronium.
GefitinibThe serum concentration of Vecuronium can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Vecuronium can be increased when it is combined with Genistein.
Ginkgo bilobaThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Ginkgo biloba.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Vecuronium is combined with Glucagon recombinant.
GlyburideThe serum concentration of Vecuronium can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Vecuronium can be increased when it is combined with Glycerol.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Vecuronium.
GlycopyrroniumVecuronium may increase the anticholinergic activities of Glycopyrronium.
Gramicidin DThe serum concentration of Vecuronium can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Vecuronium can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Vecuronium can be increased when it is combined with Haloperidol.
HeroinThe risk or severity of adverse effects can be increased when Vecuronium is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Hexamethonium.
HomatropineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Homatropine.
Huperzine AThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Huperzine A.
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Vecuronium.
HydrocodoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Hydrocodone.
HydrocortisoneThe serum concentration of Vecuronium can be increased when it is combined with Hydrocortisone.
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Vecuronium.
HydromorphoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Hydromorphone.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Vecuronium.
IdelalisibThe serum concentration of Vecuronium can be increased when it is combined with Idelalisib.
ImatinibThe serum concentration of Vecuronium can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Vecuronium can be increased when it is combined with Imipramine.
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Vecuronium.
IndinavirThe serum concentration of Vecuronium can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Vecuronium can be increased when it is combined with Indomethacin.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Vecuronium.
IsavuconazoniumThe serum concentration of Vecuronium can be increased when it is combined with Isavuconazonium.
IsoflurophateThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Isoflurophate.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Vecuronium.
ItraconazoleThe serum concentration of Vecuronium can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Vecuronium can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Vecuronium can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Vecuronium can be increased when it is combined with Ketamine.
KetobemidoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Ketobemidone.
KetoconazoleThe serum concentration of Vecuronium can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Vecuronium can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Vecuronium can be increased when it is combined with Lapatinib.
LevofloxacinThe serum concentration of Vecuronium can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Vecuronium is combined with Levomethadyl Acetate.
LevorphanolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Levorphanol.
LevothyroxineThe serum concentration of Vecuronium can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Vecuronium can be increased when it is combined with Lidocaine.
LiothyronineThe serum concentration of Vecuronium can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Vecuronium can be decreased when it is combined with Liotrix.
LisinoprilThe serum concentration of Vecuronium can be increased when it is combined with Lisinopril.
LofentanilThe risk or severity of adverse effects can be increased when Vecuronium is combined with Lofentanil.
LomitapideThe serum concentration of Vecuronium can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Vecuronium can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Vecuronium can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Vecuronium can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Vecuronium can be increased when it is combined with Losartan.
LovastatinThe serum concentration of Vecuronium can be increased when it is combined with Lovastatin.
LumacaftorThe serum concentration of Vecuronium can be decreased when it is combined with Lumacaftor.
MalathionThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Malathion.
MaprotilineThe serum concentration of Vecuronium can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Vecuronium can be increased when it is combined with Mebendazole.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Vecuronium.
MefloquineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Mefloquine.
Megestrol acetateThe serum concentration of Vecuronium can be increased when it is combined with Megestrol acetate.
MemantineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Memantine.
MeprobamateThe serum concentration of Vecuronium can be increased when it is combined with Meprobamate.
MethadoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Methadone.
MethadoneThe serum concentration of Vecuronium can be increased when it is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Vecuronium is combined with Methadyl Acetate.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Vecuronium.
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Vecuronium.
MetixeneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Metixene.
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Vecuronium.
MetoprololThe serum concentration of Vecuronium can be increased when it is combined with Metoprolol.
MianserinMianserin may increase the anticholinergic activities of Vecuronium.
MibefradilThe serum concentration of Vecuronium can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Vecuronium can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Vecuronium can be decreased when it is combined with Midazolam.
MifepristoneThe serum concentration of Vecuronium can be decreased when it is combined with Mifepristone.
MinaprineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Minaprine.
MirabegronThe risk or severity of adverse effects can be increased when Vecuronium is combined with Mirabegron.
MitomycinThe serum concentration of Vecuronium can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Vecuronium can be decreased when it is combined with Mitoxantrone.
MorphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Morphine.
MorphineThe serum concentration of Vecuronium can be increased when it is combined with Morphine.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Vecuronium is combined with N-butylscopolammonium bromide.
NabiloneVecuronium may increase the tachycardic activities of Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Nalbuphine.
NaltrexoneThe serum concentration of Vecuronium can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Vecuronium can be increased when it is combined with Naringenin.
NefazodoneThe serum concentration of Vecuronium can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Vecuronium can be decreased when it is combined with Nelfinavir.
NeostigmineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Neostigmine.
NicardipineThe serum concentration of Vecuronium can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Vecuronium can be decreased when it is combined with Nifedipine.
NilotinibThe serum concentration of Vecuronium can be increased when it is combined with Nilotinib.
NisoldipineThe serum concentration of Vecuronium can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Vecuronium can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Vecuronium can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Vecuronium can be decreased when it is combined with Norethisterone.
NormethadoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Normethadone.
NVA237The risk or severity of adverse effects can be increased when Vecuronium is combined with NVA237.
OmeprazoleThe serum concentration of Vecuronium can be increased when it is combined with Omeprazole.
OpiumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Opium.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Vecuronium.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Vecuronium.
OxycodoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Vecuronium is combined with Oxymorphone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Vecuronium.
P-NitrophenolThe serum concentration of Vecuronium can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Vecuronium can be increased when it is combined with Paclitaxel.
Palmitic AcidThe serum concentration of Vecuronium can be increased when it is combined with Palmitic Acid.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Vecuronium.
PantoprazoleThe serum concentration of Vecuronium can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Vecuronium can be increased when it is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Pentazocine.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Vecuronium.
PerindoprilThe serum concentration of Vecuronium can be increased when it is combined with Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Vecuronium is combined with Pethidine.
PhenobarbitalThe serum concentration of Vecuronium can be decreased when it is combined with Phenobarbital.
PhysostigmineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Physostigmine.
PimozideThe serum concentration of Vecuronium can be increased when it is combined with Pimozide.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Vecuronium.
PiperacillinPiperacillin may increase the neuromuscular blocking activities of Vecuronium.
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Vecuronium.
Platelet Activating FactorThe serum concentration of Vecuronium can be decreased when it is combined with Platelet Activating Factor.
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Vecuronium.
PonatinibThe serum concentration of Vecuronium can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Vecuronium can be increased when it is combined with Posaconazole.
Potassium ChlorideVecuronium may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Vecuronium.
PravastatinThe serum concentration of Vecuronium can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Vecuronium can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Vecuronium can be increased when it is combined with Prednisone.
ProbenecidThe serum concentration of Vecuronium can be increased when it is combined with Probenecid.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Vecuronium.
ProgesteroneThe serum concentration of Vecuronium can be decreased when it is combined with Progesterone.
PromethazineThe serum concentration of Vecuronium can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Vecuronium can be increased when it is combined with Propafenone.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Vecuronium.
PropranololThe serum concentration of Vecuronium can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Vecuronium can be increased when it is combined with Protriptyline.
PyridostigmineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Pyridostigmine.
QuercetinThe serum concentration of Vecuronium can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Vecuronium can be increased when it is combined with Quinacrine.
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Vecuronium.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Vecuronium.
QuinineThe serum concentration of Vecuronium can be increased when it is combined with Quinine.
RamosetronVecuronium may increase the constipating activities of Ramosetron.
RanitidineThe serum concentration of Vecuronium can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Vecuronium can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Vecuronium can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Vecuronium can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Vecuronium is combined with Remifentanil.
ReserpineThe serum concentration of Vecuronium can be decreased when it is combined with Reserpine.
RifampicinThe serum concentration of Vecuronium can be decreased when it is combined with Rifampicin.
RilpivirineThe serum concentration of Vecuronium can be increased when it is combined with Rilpivirine.
RitonavirThe serum concentration of Vecuronium can be decreased when it is combined with Ritonavir.
RivastigmineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Rivastigmine.
RolapitantThe serum concentration of Vecuronium can be increased when it is combined with Rolapitant.
SaquinavirThe serum concentration of Vecuronium can be decreased when it is combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vecuronium.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Vecuronium is combined with Scopolamine butylbromide.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Vecuronium.
SelegilineThe serum concentration of Vecuronium can be increased when it is combined with Selegiline.
SertralineThe serum concentration of Vecuronium can be increased when it is combined with Sertraline.
SimeprevirThe serum concentration of Vecuronium can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Vecuronium can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Vecuronium can be decreased when it is combined with Sirolimus.
SolifenacinThe risk or severity of adverse effects can be increased when Vecuronium is combined with Solifenacin.
SorafenibThe serum concentration of Vecuronium can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Vecuronium can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Vecuronium can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Vecuronium can be increased when it is combined with Staurosporine.
StreptozocinThe serum concentration of Vecuronium can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Vecuronium is combined with Sufentanil.
SulfinpyrazoneThe serum concentration of Vecuronium can be increased when it is combined with Sulfinpyrazone.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Vecuronium.
SumatriptanThe serum concentration of Vecuronium can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Vecuronium can be increased when it is combined with Sunitinib.
TacrineThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Tacrine.
TacrolimusThe serum concentration of Vecuronium can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Vecuronium can be decreased when it is combined with Tamoxifen.
TapentadolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Tapentadol.
Taurocholic AcidThe serum concentration of Vecuronium can be increased when it is combined with Taurocholic Acid.
TelmisartanThe serum concentration of Vecuronium can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Vecuronium can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Vecuronium can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Vecuronium can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Vecuronium can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Vecuronium can be increased when it is combined with Testosterone.
TicagrelorThe serum concentration of Vecuronium can be increased when it is combined with Ticagrelor.
TiotropiumVecuronium may increase the anticholinergic activities of Tiotropium.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Vecuronium.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Vecuronium.
TolvaptanThe serum concentration of Vecuronium can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Vecuronium is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Vecuronium is combined with Tramadol.
TrazodoneThe serum concentration of Vecuronium can be decreased when it is combined with Trazodone.
TrichlorfonThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Trichlorfon.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Vecuronium.
TrifluoperazineThe serum concentration of Vecuronium can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Vecuronium can be increased when it is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Vecuronium.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Vecuronium.
TrimethoprimThe serum concentration of Vecuronium can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Vecuronium can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Vecuronium can be increased when it is combined with Troleandomycin.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Vecuronium.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Vecuronium.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Vecuronium.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Vecuronium.
UmeclidiniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Umeclidinium.
VenlafaxineThe serum concentration of Vecuronium can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Vecuronium can be decreased when it is combined with Verapamil.
VinblastineThe serum concentration of Vecuronium can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Vecuronium can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Vecuronium can be increased when it is combined with Vinorelbine.
ZimelidineThe serum concentration of Vecuronium can be increased when it is combined with Zimelidine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Drug binding
Specific Function:
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name:
CHRNA2
Uniprot ID:
Q15822
Molecular Weight:
59764.82 Da
References
  1. Jonsson Fagerlund M, Dabrowski M, Eriksson LI: Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology. 2009 Jun;110(6):1244-52. doi: 10.1097/ALN.0b013e31819fade3. [PubMed:19417616 ]
  2. Liu M, Dilger JP: Synergy between pairs of competitive antagonists at adult human muscle acetylcholine receptors. Anesth Analg. 2008 Aug;107(2):525-33. doi: 10.1213/ane.0b013e31817b4469. [PubMed:18633030 ]
  3. Paul M, Fokt RM, Kindler CH, Dipp NC, Yost CS: Characterization of the interactions between volatile anesthetics and neuromuscular blockers at the muscle nicotinic acetylcholine receptor. Anesth Analg. 2002 Aug;95(2):362-7, table of contents. [PubMed:12145052 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Molecular Weight:
61153.345 Da
References
  1. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997 Jun;51(6):913-21. [PubMed:9187257 ]
  2. Zhang L, Schaner ME, Giacomini KM: Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998 Jul;286(1):354-61. [PubMed:9655880 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Smit JW, Weert B, Schinkel AH, Meijer DK: Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs. J Pharmacol Exp Ther. 1998 Jul;286(1):321-7. [PubMed:9655875 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 12:08 / Updated on August 17, 2016 12:23